If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
This medicinal product has been authorised under a conditional approval scheme. This means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed at least every year and this Summary of Product Characteristics will be updated as necessary.
Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)) was previously called COVID-19 mRNA Vaccine BNT162b2 and supplied under a Regulation 174 temporary supply authorisation. Following conditional Marketing Authorisation, the vaccine is now known by the brand name Comirnaty. If you have a question regarding the COVID-19 mRNA Vaccine BNT162b2 please submit an enquiry on our webform and clearly state this in the question field. The product label information for COVID-19 mRNA Vaccine BNT162b2 can be accessed on Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - GOV.UK (www.gov.uk)
Healthcare Professionals located in Northern Ireland
If you are a Healthcare Professional based in Northern Ireland with a question on Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)), please submit your enquiry on our webform and clearly state this in the question field. The Comirnaty Summary of Product Characteristics for Northern Ireland can be accessed on https://www.emcmedicines.com/en-gb/northernireland
The information provided below is for customers located in Great Britain.
This medicinal product has been authorised under a conditional approval scheme. This means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed at least every year and the Summary of Product Characteristics will be updated as necessary.
Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)) was previously called COVID-19 mRNA Vaccine BNT162b2 and supplied under a Regulation 174 temporary supply authorisation. Following conditional Marketing Authorisation, the vaccine is now known by the brand name Comirnaty. If you have a question regarding the COVID-19 mRNA Vaccine BNT162b2 please submit an enquiry on our webform and clearly state this in the question field. The product label information for COVID-19 mRNA Vaccine BNT162b2 can be accessed on Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - GOV.UK (www.gov.uk)
Healthcare Professionals located in Northern Ireland
If you are a Healthcare Professional based in Northern Ireland with a question on Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)), please submit your enquiry on our webform and clearly state this in the question field. The Comirnaty Summary of Product Characteristics for Northern Ireland can be accessed on https://www.emcmedicines.com/en-gb/northernireland
The information provided below is for customers located in Great Britain.
COMIRNATY ▼ (Covid-19 mRNA vaccine)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
This medicinal product has been authorised under a conditional approval scheme. This means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed at least every year and this Summary of Product Characteristics will be updated as necessary.
Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)) was previously called COVID-19 mRNA Vaccine BNT162b2 and supplied under a Regulation 174 temporary supply authorisation. Following conditional Marketing Authorisation, the vaccine is now known by the brand name Comirnaty. If you have a question regarding the COVID-19 mRNA Vaccine BNT162b2 please submit an enquiry on our webform and clearly state this in the question field. The product label information for COVID-19 mRNA Vaccine BNT162b2 can be accessed on Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - GOV.UK (www.gov.uk)
Healthcare Professionals located in Northern Ireland
If you are a Healthcare Professional based in Northern Ireland with a question on Comirnaty (COVID-19 mRNA Vaccine (nucleoside modified)), please submit your enquiry on our webform and clearly state this in the question field. The Comirnaty Summary of Product Characteristics for Northern Ireland can be accessed on https://www.emcmedicines.com/en-gb/northernireland
The information provided below is for customers located in Great Britain.
COMIRNATY ▼ Quick Finder
Chat online with Pfizer Medical Information regarding your enquiry on the COVID-19 mRNA Vaccine BNT162b2. Please select COVID-19 mRNA Vaccine BNT162b2 on the first menu.
Submit your medical enquiry on a Pfizer medicine
If you are concerned about an adverse event it should be reported on a Yellow Card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. When reporting please include the vaccine brand and batch/Lot number if available.
Alternatively, adverse events of concern in association with the COVID-19 mRNA vaccine can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com
Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymized form) and dual reporting will create unnecessary duplicates.